Osmind

11/14/2025

hat's a wrap on BHT2025! 🌊
Osmind was proud to sponsor three days in San Diego with innovators, clinicians, and advocates working to advance behavioral health through technology.

Big takeaways: Tracking data is only valuable if we measure what actually matters to patients. And proactive outreach (reaching people before crisis) changes how we think about access to care. "An ounce of prevention is worth a pound of cure."

At Osmind, we're building tools that help psychiatrists deliver evidence-based, measurement-driven care that focuses on outcomes that matter. Conferences like this remind us why that work is so important.

Thanks to everyone who made Behavioral Health Tech such a thought-provoking few days.

11/11/2025

This Veterans Day, we honor those who serve and those who care for them.

At Osmind, we're privileged to support clinicians and researchers working to advance PTSD treatment, from ketamine therapy to new interventional approaches.

Special thanks to William Sauvé, MD, who served 11 years as an active duty Navy psychiatrist before joining us as Chief Medical Officer. Thank you for your service, Dr. Will.

11/07/2025

Here's what you missed this month in the Osmind Psychiatry Collective, a community of 2,500+ innovative practitioners advancing interventional psychiatry through case discussions, treatment protocols, and peer consultation:

•TMS and ketamine treatment strategies: Members discussed Medicaid coverage for TMS, alternating TMS and ketamine for MDD and postpartum depression, and the potential of VNS. William Sauvé, MD shared insights on a systematic review examining depression treatment costs.

•L*D microdosing research: William Sauvé, MD shared findings from an open-label trial on L*D microdosing for depression, while Dr. Brittany Albright discussed a systematic review on ketogenic diet's impact on depressive symptoms.

•Ketamine for PTSD real-world evidence: L. Alison McInnes MD, MS presented large-scale ketamine infusion therapy data for PTSD, highlighting significant response rates and clinical implementation strategies.

•Patient acquisition strategies wrap-up: The October theme concluded with polls and discussions on improving patient workflows and practice growth tactics that actually work.

•CGMs in psychiatry discussion: Members explored using continuous glucose monitors for psychiatric symptom management, diving into the metabolic-psychiatric connection.

•Community growth: 28 new members joined, bringing fresh perspectives and expanding the network of forward-thinking clinicians.

Stay tuned for Novembers theme: Hiring and retention for your growing psychiatry practice!

Ready to join the conversation? Join using the links in comments below 👇

11/06/2025

You never know which conversation will spark a wave of transformation in behavioral health care.

That's why Osmind is sponsoring the Behavioral Health Tech Conference 2025. As a Public Benefit Corporation serving 800+ independent psychiatry practices, we've seen how technology and collaboration make mental health treatment more accessible, and we know the best ideas come from bringing the right people together.

11/05/2025

Most psychiatric treatments lose effectiveness over time. Vagal nerve stimulation does the opposite.

Lucian Manu, M.D. has helped over 20 patients access VNS at Stony Brook University, many who'd exhausted every other option.

Patients don't just maintain improvement. They keep getting better. Month after month. Year after year.

In our latest Psychiatry Tomorrow episode, Dr. Manu, Carlene MacMillan, MD, FCTMSS,DFAACAP, and William Sauvé, MD break down:

• Why a scientist's observation at Lamaze class led to this breakthrough

• How VNS reduces reliance on weekly ketamine (freeing up your clinic capacity)

• Why Medicare covers it now after 15 years of insurance denials, and how to navigate appeals

• What the procedure actually involves (analogous to pacemaker implantation)
VNS creates a "floor" patients don't fall below.

As Dr. Manu puts it: "It's like acrobats at the circus; when they fall, they have that net."

This episode offers practical guidance on selection criteria, insurance navigation, and accessing the RECOVER trial's sites nationwide.

Listen now: Search "Psychiatry Tomorrow" on your podcast player or within the blog breakdown below. 🎧

What's your experience with VNS? Have you considered it for treatment-resistant patients? 👇

Vagal nerve stimulation (VNS) for depression improves progressively over 12-24 months with remarkably low relapse rates. Learn patient selection criteria, Medicare RECOVER trial access, insurance appeals process, and how VNS creates a clinical "floor" preventing deepest episodes. Expert insights fro...

10/30/2025

Solo practice means you're good at what you do. It also means you're isolated.

Dr. Jacob Behrens, MD runs Envision ADHD in Wisconsin. He joined The Psychiatry Collective to stay current on emerging treatments—but discovered something more valuable than research updates.

"Just having a community where you get to learn from others, see how other people might be using different tools, how they might fit it into their workflows... I think: how can I take this and adapt it within my own system? That's the most direct benefit."

This community tackles real practice challenges: outcome-based care workflows, AI integration, patient rating scales, documentation strategies, and burning case questions.

"Instead of mindlessly scrolling, I have something productive. It keeps me excited, keeps me engaged. I feel like I have something to offer when I answer a question."

Join The Psychiatry Collective and connect with clinicians solving the same problems you face every day (link in comments below):

10/28/2025

Food fell out of the refrigerator. For most people, mildly annoying. For one patient with depression, it used to trigger hours of rage and dysregulation.

After TMS treatment, it happened again. But this time, he picked up the food, put it back, and moved on. His wife stood there stunned.

Impulse control came back online. That's one of many things that TMS does.

But TMS won't help that patient reprocess childhood trauma or shift their relationship to painful memories. That's what ketamine does.

Different tools for different jobs.

In a recent webinar hosted by Psychedelic Medicine Association, David Feifel, MD, PhD (who founded the world's first ketamine clinic) and William Sauvé, MD, Chief Medical Officer at Osmind, explain why combining ketamine and TMS often works better than either alone:

•Ketamine gets you unstuck fast.
•TMS keeps you moving long-term.
•Patients can do both with complementary effects.

In this guide, we cover:
→ Practical patient selection criteria
→ Insurance coverage realities (TMS and Spravato are covered, ketamine typically isn't)
→ Clinical decision frameworks for combination therapy

Depression doesn't have a single cause, so why would it have a single solution?

Ketamine works fast but fades. TMS builds slowly but lasts. Spravato is covered by insurance. Learn when combinin treatments for depression delivers what one can't alone—and which patients benefit most.

10/27/2025

We're hiring: VP of Finance

We're looking for an SF-based finance leader to help scale our next chapter.

You'll partner with our leadership team to sharpen decision-making as we grow our network of 800+ independent psychiatry practices, contribute to research, and move the needle on the mental health crisis.

Your role: evolve the finance function, lead strategic planning, and serve as a trusted advisor to our founders and leadership team. You'll work on everything from annual budgeting to capital allocation strategy, building the team and infrastructure to support our growth.

Hybrid role in San Francisco, reporting to our CEO.

Interested or know someone who'd be a great fit? Learn more and apply:

About Osmind Osmind is a technology, services, and data company focused exclusively on psychiatry. Mental health disorders are one of the leading causes of death worldwide and are tied to shortening lifespans. Yet, we have cause for hope: there have been developments in new psychiatric medications s...

10/23/2025

Nine out of twenty patients were on GLP-1 medications. Not at a weight loss clinic. At a psychiatry practice.

Brittany Albright MD, MPH counted at the end of a typical clinic day and wasn't surprised. About 43% of patients with major depression have obesity.

GLP-1 receptors sit throughout your mesolimbic system—the brain's reward pathway. The VTA, nucleus accumbens, everywhere dopamine works. That's why these medications reduce alcohol cravings, to***co cravings, and compulsive eating.

A February 2025 JAMA Psychiatry study showed semaglutide significantly reduced drinking episodes in patients with alcohol use disorder. At relatively low doses.

But psychiatrists keep asking: "Are we allowed to prescribe these?" GLP-1 RAs are FDA-approved primarily for obesity and diabetes, not specifically for psychiatric disorders yet, but there is strong interest and emerging evidence around their psychiatric benefits and prescribing uses.

Albright's response: "Are we not allowed to prescribe metformin? Valproic acid? Propranolol? We're kidding ourselves if we're not treating obesity."

The field is moving past the monoamine myth toward a model that accounts for inflammation, metabolic dysfunction, chronic stress changing your brain's fuel supply.

By 2030, over 50% of US adults will have obesity. We have 75,000 psychiatrists and psychiatric practitioners. We have 60 million people needing mental health care right now.

The math doesn't work unless we start treating the metabolic roots of psychiatric disease.

Listen to Dr. Will Sauvé and Dr. Brittany Albright discuss:
•Brain mechanisms behind GLP-1s and addiction
•Should a psychiatrist ever prescribe a GLP-1 medication?
•Patient selection beyond BMI
•Force multipliers for scaling psychiatric care

Read the guide (linked below) or listen on your favorite podcast platform by searching “Psychiatry Tomorrow”

GLP-1 receptors throughout the brain's reward pathway make these medications psychiatric tools for treating depression and other mental health issues, not just metabolic issues. Learn evidence-based patient selection criteria for treating cravings, compulsivity, and metabolic dysfunction in psychiat...

10/15/2025

“This TMS chair is not Santa’s sleigh; it doesn’t run on belief.” William Sauvé, MD’s favorite patient story captures how TMS differs from traditional psychiatric treatment.

A man agreed to TMS only because his wife was pressuring him. He told Sauvé point-blank: “I don’t believe in this. I think it’s silly.”

By the end of treatment? Complete remission. “I’ve never been so happy to be wrong,” he admitted. “Our entire careers, we’ve been telling people you need to have faith in that pill for it to work,” Sauvé explains.

“You’re somehow sabotaging your treatment.” TMS changes that. The machine stimulates your brain whether you believe in it or not. No faith required, no self-blame if it doesn’t work, no pressure to “try harder.”

For patients already carrying the weight of their illness, removing the burden of belief can be transformative.

Listen to the full conversation by searching “Psychiatry Tomorrow” on your favorite podcast platform!

10/15/2025

"This TMS chair is not Santa's sleigh; it doesn't run on belief."

William Sauvé, MD's favorite patient story captures how TMS differs from traditional psychiatric treatment.

A man agreed to TMS only because his wife was pressuring him. He told Sauvé point-blank: "I don't believe in this. I think it's silly."

By the end of treatment? Complete remission. "I've never been so happy to be wrong," he admitted.

"Our entire careers, we've been telling people you need to have faith in that pill for it to work," Sauvé explains. "You're somehow sabotaging your treatment."

TMS changes that. The machine stimulates your brain whether you believe in it or not. No faith required, no self-blame if it doesn't work, no pressure to "try harder."

For patients already carrying the weight of their illness, removing the burden of belief can be transformative.

Listen to the full conversation by searching "Psychiatry Tomorrow" on your favorite podcast platform, or read/listen on our blog linked below!

10/10/2025

Mental healthcare takes a village. We need each other. From supportive communities and environments that foster well-being, to innovative treatments for those facing treatment-resistant depression.

Today, we’re grateful for the researchers asking hard questions, the clinicians showing up every day, and the pioneers trying new approaches when the old ones aren’t enough. You’re making a difference.

Check on your loved ones. Check in with yourself. We’re here for each other.